Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + Chemotherapy in Advanced Urothelial Cancer
NCT00005831Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2000
- Primary completion
- Aug 2004
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoint: Cardiac toxicity rate up to 7 years. Started Mar 2000; status: completed.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00005831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005831.